Table 1.
Patients' characteristics.
| Patient no. | Age | Sex | Disease activity | Therapy |
|---|---|---|---|---|
| Crohn's disease patients | ||||
| 1 | 29 | M | Remission | MTX |
| 2 | 49 | M | Remission | IFX |
| 3 | 28 | F | Remission | Steroids |
| 4 | 58 | M | Remission | No TP |
| 5 | 29 | M | Remission | IFX |
| 6 | 22 | M | Remission | IFX |
| 7 | 41 | F | Remission | Un |
| 8 | 35 | M | Remission | IFX |
| 9 | 14 | M | Remission | IFX |
| 10 | 62 | M | Remission | IFX |
| 11 | 31 | F | Remission | IFX |
| 12 | 40 | M | Remission | IFX |
| 13 | 40 | F | Remission | IFX |
| 14 | 46 | M | Remission | IFX |
| 15 | 45 | F | Active | IFX |
| 16 | 25 | F | Active | IFX |
| 17 | 24 | F | Active | IFX |
| 18 | 45 | F | Active | IFX |
| 19 | 56 | M | Active | Un |
| 20 | 56 | M | Active | Un |
| 21 | 29 | M | Active | Un |
| 22 | 46 | F | Active | Steroids + azathioprine |
| 23 | 46 | M | Active | IFX |
| 24 | 24 | M | Active | IFX |
| 25 | 35 | M | Active | Un |
| 26 | 24 | F | Active | IFX |
| 27 | 48 | F | Active | IFX + antibiotics |
| 28 | 64 | M | Active | Steroids + MTX |
| Ulcerative colitis patients | ||||
| 29 | 54 | M | Remission | Mesalasine |
| 30 | 84 | M | Remission | Mesalazine |
| 31 | 43 | F | Remission | Mesalazine |
| 32 | 23 | F | Remission | Mercaptopurine |
| 33 | 62 | F | Remission | No TP |
| 34 | 31 | F | Remission | IFX |
| 35 | 43 | M | Remission | IFX |
| 36 | 48 | M | Remission | No TP |
| 37 | 32 | F | Remission | IFX |
| 38 | 44 | M | Remission | IFX |
| 39 | 49 | M | Remission | No TP |
| 40 | 21 | F | Remission | IFX |
| 41 | 47 | F | Remission | Mesalazine |
| 42 | 26 | F | Active | IFX |
| 43 | 61 | M | Active | IFX |
| 44 | 44 | M | Active | IFX |
| 45 | 34 | M | Active | Un |
| 46 | 71 | F | Active | No TP |
Patients were categorized in remission or in active phase of the disease by the clinician involved in the study (P.M.). MTX: methotrexate; IFX: infliximab; Un: unknown; No TP, no therapy; M: male; F: female.